| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 0 | 0 | 0 | 0 | 12.332 | 23.530 | 23.964 | 23.992 | 28.550 |
| Total Income - EUR | 0 | 0 | 0 | 0 | 0 | 12.506 | 23.530 | 23.964 | 23.992 | 28.550 |
| Total Expenses - EUR | 16.811 | 8.883 | 8.239 | 8.148 | 6.469 | 7.268 | 6.509 | 7.095 | 8.408 | 23.295 |
| Gross Profit/Loss - EUR | -16.810 | -8.883 | -8.239 | -8.148 | -6.469 | 5.238 | 17.021 | 16.869 | 15.584 | 5.255 |
| Net Profit/Loss - EUR | -16.810 | -8.883 | -9.992 | -8.148 | -6.469 | 5.113 | 16.786 | 16.629 | 15.344 | 4.969 |
| Employees | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Pharma Millenium Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 78.628 | 71.905 | 65.698 | 64.493 | 63.244 | 62.045 | 60.669 | 60.857 | 60.673 | 46.815 |
| Current Assets | 6.889 | 6.711 | 6.702 | 6.972 | 6.887 | 6.049 | 6.682 | 5.862 | 7.904 | 2.284 |
| Inventories | 230 | 228 | 224 | 220 | 215 | 211 | 207 | 207 | 207 | 0 |
| Receivables | 6.235 | 6.338 | 6.361 | 6.688 | 6.612 | 5.160 | 5.046 | 5.062 | 5.855 | 494 |
| Cash | 424 | 146 | 118 | 65 | 59 | 677 | 1.429 | 593 | 1.843 | 1.790 |
| Shareholders Funds | -39.316 | -47.798 | -56.981 | -64.084 | -69.312 | -62.885 | -44.704 | -28.214 | -12.784 | -7.744 |
| Social Capital | 90 | 89 | 88 | 86 | 84 | 83 | 81 | 81 | 81 | 80 |
| Debts | 124.833 | 126.583 | 129.516 | 135.549 | 139.442 | 130.979 | 112.055 | 94.933 | 81.361 | 56.843 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "6820 - 6820" | |||||||||
| CAEN Financial Year |
6820
|
|||||||||
Comments - Pharma Millenium Srl